Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioInvent International AB ( (SE:BINV) ) has provided an update.
BioInvent International AB is a clinical-stage biotechnology company specializing in immuno-oncology, developing novel immuno-modulatory antibody therapies for hematological cancers and solid tumors. Leveraging its proprietary F.I.R.S.T. discovery platform, the company advances its own clinical pipeline while securing revenues from research collaborations, licensing deals, and third-party antibody manufacturing.
The company has invited investors, analysts, and media to a webcast and conference call on 26 February 2026 for the presentation of its 2025 year-end report, to be held in English by CEO Martin Welschof and CFO Stefan Ericsson. The event is designed to provide detailed financial and operational updates and will later be accessible via the company’s website, underscoring ongoing engagement with the capital markets and other stakeholders ahead of a potentially pivotal phase in its clinical and partnering activities.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK31.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on discovering and developing first-in-class immuno-modulatory antibodies for cancer therapy. Its pipeline includes Phase 1/2 programs targeting hematological malignancies and solid tumors, supported by its proprietary F.I.R.S.T. technology platform, which identifies novel targets and antibodies and underpins both internal development and partnering opportunities.
The company also generates revenue through research collaborations, license agreements with major pharmaceutical partners, and contract manufacturing of antibodies through its fully integrated production unit. This diversified model provides multiple income streams while advancing BioInvent’s own oncology pipeline, reinforcing its position within the immuno-oncology segment of the biotech industry.
Average Trading Volume: 102,100
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.73B
Learn more about BINV stock on TipRanks’ Stock Analysis page.